Pathfinders in Biopharma

46 Afleveringen

1. Uncertainty reigns, but opportunity persists for biotech’s 2025

   Gepubliceerd: 7-2-2025
2. Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments

   Gepubliceerd: 22-11-2024
3. Former Investor Who Chose Broadcasting Over Biotech ETFs

   Gepubliceerd: 30-9-2024
4. Can AI Solve Molecule Mysteries that will Unlock Simpler Drug Discovery?

   Gepubliceerd: 29-8-2024
5. Shots-on-Goal Licensing Company Aims for Breakthroughs

   Gepubliceerd: 19-7-2024
6. Why Biopharma Needs to Tell Better Stories on Novel Drugs

   Gepubliceerd: 11-7-2024
7. Venture capital velocity: What’s driving renewed momentum in biotech?

   Gepubliceerd: 8-7-2024
8. Pharma Understands Phase One Data – But Does the Market?

   Gepubliceerd: 21-6-2024
9. Davern Capital sees GLP-1 Opportunities Beyond Obesity

   Gepubliceerd: 14-6-2024
10. Betting on Healthcare’s Future Hits – and Misses

    Gepubliceerd: 10-6-2024
11. Innovation and an Aging Population Drive MedTech

    Gepubliceerd: 5-6-2024
12. Biopharma Investors See Opportunities in Targeted Treatments and Gene Editing

    Gepubliceerd: 3-6-2024
13. Biotech with a Mission to Target Unmet Cancer Needs

    Gepubliceerd: 31-5-2024
14. The M&A Pool Set to Accelerate Biotech Innovation

    Gepubliceerd: 3-4-2024
15. How PIPEs finally unblocked biotech’s funding flows

    Gepubliceerd: 29-3-2024
16. Disruptive Forces in Healthcare: Why HCIT is finally set to bounce back

    Gepubliceerd: 7-3-2024
17. Will the Biotech Rebound Run into Pricing Policy Obstacles?

    Gepubliceerd: 27-2-2024
18. Few IPOs but plenty of follow-on for biotech in 2023

    Gepubliceerd: 22-1-2024
19. U.S. Outlook: Will the US economy achieve a soft landing in 2024?

    Gepubliceerd: 29-12-2023
20. Raising Venture Capital: A New Playbook for A New Era in Biotech

    Gepubliceerd: 22-11-2023